FY2024 EPS Estimates for Option Care Health, Inc. Increased by Barrington Research (NASDAQ:OPCH)

Option Care Health, Inc. (NASDAQ:OPCH) – Analysts at Barrington Research increased their FY2024 EPS estimates for Option Care Health in a research note issued to investors on Wednesday, April 24th. Barrington Research analyst M. Petusky now expects that the company will post earnings of $1.15 per share for the year, up from their previous forecast of $1.10. Barrington Research has a “Outperform” rating and a $38.00 price objective on the stock. The consensus estimate for Option Care Health’s current full-year earnings is $1.17 per share. Barrington Research also issued estimates for Option Care Health’s FY2025 earnings at $1.35 EPS.

Separately, Jefferies Financial Group lifted their target price on shares of Option Care Health from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, March 4th.

Option Care Health Price Performance

Shares of Option Care Health stock opened at $29.61 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. The firm has a fifty day simple moving average of $31.96 and a 200-day simple moving average of $31.48. The stock has a market capitalization of $5.15 billion, a price-to-earnings ratio of 19.48, a PEG ratio of 1.65 and a beta of 1.22. Option Care Health has a 1-year low of $24.23 and a 1-year high of $35.74.

Option Care Health (NASDAQ:OPCH) last posted its earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.10 billion. Option Care Health had a return on equity of 18.92% and a net margin of 6.15%. The business’s revenue was up 12.8% compared to the same quarter last year. During the same period last year, the company earned $0.21 earnings per share.

Institutional Trading of Option Care Health

Hedge funds have recently modified their holdings of the company. Principal Securities Inc. bought a new position in shares of Option Care Health during the 4th quarter worth about $27,000. Parallel Advisors LLC lifted its stake in Option Care Health by 130.2% during the fourth quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock worth $28,000 after purchasing an additional 478 shares during the period. TFO Wealth Partners LLC boosted its holdings in Option Care Health by 24,625.0% during the fourth quarter. TFO Wealth Partners LLC now owns 989 shares of the company’s stock valued at $33,000 after purchasing an additional 985 shares in the last quarter. First Horizon Advisors Inc. bought a new stake in shares of Option Care Health in the 3rd quarter valued at approximately $37,000. Finally, Park Place Capital Corp raised its holdings in shares of Option Care Health by 48.4% in the 1st quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock worth $38,000 after buying an additional 372 shares in the last quarter. Institutional investors own 98.05% of the company’s stock.

Insider Activity

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were bought at an average cost of $31.55 per share, for a total transaction of $1,104,250.00. Following the transaction, the director now directly owns 269,528 shares of the company’s stock, valued at approximately $8,503,608.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.64% of the stock is owned by company insiders.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.